Co-Scientist: repurposed drugs against liver fibrosis
In Gary Peltz's Stanford lab, two of the three existing drugs proposed by Co-Scientist blocked fibrosis and promoted regeneration in human liver cells, while Peltz's own two choices showed no benefit. The anticancer drug vorinostat blocked 91% of a damage response that can lead to scarring. Cell experiments only; published in Advanced Science.
Technology: Co-Scientist
Family AI Co-Scientist: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The anti-fibrotic efficacy and toxicity of 25 drugs were assessed serially in human liver organoids grown in microwells; Co-Scientist's candidates were tested in cells alongside the authors' own picks.
- Still unknown: Not reported.
- AI role: The AI co-scientist multi-agent system proposed three candidate drugs with reasoning, and helped direct their experimental characterization.
Evidence sources: https://deepmind.google/blog/uncovering-repurposed-medicines-to-fight-liver-fibrosis/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1002/advs.202508751&resultType=core&format=json
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 27 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.